THU0416 Attrition Bias in Rheumatoid Arthritis Randomised Trials with Different Modified Intention-To-Treat Approaches: A Meta-Epidemiological Study: Table 1

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 326.1-326
Author(s):  
A. Dossing ◽  
S. Tarp ◽  
D.E. Furst ◽  
C. Gluud ◽  
J. Beyene ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Epidemiological Study ◽  
Randomised Trials ◽  
Attrition Bias ◽  
Intention To Treat

scholarly journals Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study

BMJ ◽  
2015 ◽  
Vol 350 (may27 2) ◽  
pp. h2445-h2445 ◽  
Author(s):  
I. Abraha ◽  
A. Cherubini ◽  
F. Cozzolino ◽  
R. De Florio ◽  
M. L. Luchetta ◽  
...  
Keyword(s):  
Epidemiological Study ◽  
Treatment Effect ◽  
Randomised Trials ◽  
Intention To Treat ◽  
Treat Analysis

scholarly journals Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol

BMJ Open ◽  
2014 ◽  
Vol 4 (9) ◽  
pp. e005297-e005297 ◽  
Author(s):  
A. Dossing ◽  
S. Tarp ◽  
D. E. Furst ◽  
C. Gluud ◽  
J. Beyene ◽  
...  
Keyword(s):  
Epidemiological Study ◽  
Study Protocol ◽  
Attrition Bias ◽  
Intention To Treat

scholarly journals Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis

2020 ◽  
Vol 23 (2) ◽  
pp. 184-189
Author(s):  
Ripa Akter ◽  
Walter P. Maksymowych ◽  
M. Liam Martin ◽  
David B. Hogan
Keyword(s):  
Rheumatoid Arthritis ◽  
Older Patients ◽  
Treatment Effectiveness ◽  
Remission Rate ◽  
Age Groups ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Intention To Treat ◽  
Disease Modifying ◽  
Treat Analysis

Background Biological disease-modifying antirheumatic drugs (bDMARDs) are recommended for rheumatoid arthritis (RA), but older patients reportedly experience more adverse events (AEs) and show variable treatment response. The objective of this study was to evaluate AEs and effectiveness of bDMARDs in a cohort of older patients. Methods AE and treatment effectiveness (based on DAS28 scores) data from a prospective provincial pharmacovigilance program for the years 2006–2009 in patients 55–64, 65–74, and 75+ years of age were compared. An intention to treat analysis with chisquare and unpaired t-testing for significance was performed. Results There were a total of 333 patients (156 were aged 55–64, 125 were 65–74, 52 were 75+). Those 75+ had higher disease activity and worse functional status at baseline. Among those 75+, AEs with bDMARDs were more common and likely to lead to discontinuation of therapy, be graded as severe, and classified as infectious (p < .05). Remission rate among those 75+ was significantly higher than patients 65–74. Etanercept was the most commonly used drug in all age groups. Conclusion Patients 75+ treated with bDMARDs are at a significantly greater risk of AEs, including infectious ones. The higher remission found in the oldest age group warrants further study.

scholarly journals Physiotherapy for pain: a meta-epidemiological study of randomised trials

2016 ◽  
Vol 50 (16) ◽  
pp. 965-971 ◽  
Author(s):  
Elisabeth Ginnerup-Nielsen ◽  
Robin Christensen ◽  
Kristian Thorborg ◽  
Simon Tarp ◽  
Marius Henriksen
Keyword(s):  
Epidemiological Study ◽  
Randomised Trials

scholarly journals Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials

2017 ◽  
Vol 46 (6) ◽  
pp. 699-708 ◽  
Author(s):  
Simon Tarp ◽  
Daniel E. Furst ◽  
Anna Dossing ◽  
Mikkel Østergaard ◽  
Tove Lorenzen ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Meta Analysis ◽  
Randomised Trials
Sign in / Sign up

Export Citation Format

Share Document